Loading clinical trials...
Loading clinical trials...
Intravitreal Enzyme Replacement Therapy to Prevent Retinal Disease Progression in Children With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
Conditions
Interventions
Cerliponase Alfa
Locations
1
United States
Nationwide Children's Hospital
Columbus, Ohio, United States
Start Date
November 1, 2021
Primary Completion Date
November 1, 2025
Completion Date
November 1, 2027
Last Updated
June 11, 2025
NCT04476862
NCT02678689
Lead Sponsor
David L Rogers, MD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions